Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds
Molecules · 2023
DOI: 10.3390/molecules28062499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Jakob Kljun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia. Hauptthemen laut MEDLINE: Ruthenium, Phosphines, Antineoplastic Agents, Organometallic Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovenian Research Agency, Universidad Nacional de La Plata (UNLP), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET).
Abstract (Originalsprache)
Organoruthenium pyrithione (1-hydroxypyridine-2-thione) complexes have been shown in our recent studies to be a promising family of compounds for development of new anticancer drugs. The complex [(η6-p-cymene)Ru(pyrithionato)(pta)]PF6 contains phosphine ligand pta (1,3,5-triaza-7-phosphaadamantane) as a functionality that improves the stability of the complex and its aqueous solubility. Here, we report our efforts to find pta alternatives and discover new structural elements to improve the biological properties of ruthenium anticancer drugs. The pta ligand was replaced by a selection of phosphine, phosphite, and arsine ligands to identify new functionalities, leading to improvement in inhibitory potency towards enzyme glutathione S-transferase. In addition, cytotoxicity in breast, bone, and colon cancers was investigated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chemistry and Chemical Technology, University of Ljubljana, Večna pot 113, SI-1000 Ljubljana, Slovenia.
- CEQUINOR (UNLP, CCT-CONICET La Plata, Asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Blvd. 120 N°1465, La Plata 1900, Argentina.
- Institute of Preclinical Sciences, Veterinary Faculty, University of Ljubljana, Gerbičeva 60, SI-1000 Ljubljana, Slovenia.
- Department of Biology, Biotechnical Faculty, University of LjubljanaJamnikarjeva 101, SI-1000 Ljubljana, Slovenia.
ORCID-Profile: Jakob Kljun, Kristina Sepčić, Robert Frangež, Ignacio E León, Iztok Turel
Förderung
- Slovenian Research Agency
- Universidad Nacional de La Plata (UNLP)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
- Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
- Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)
Zitieren
APA
Kljun, J., Rebernik, M., Balsa, L. M., Kladnik, J., Rapuš, U., Trobec, T., Sepčić, K., Frangež, R., León, I. E., & Turel, I. (2023). Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds. Molecules. https://doi.org/10.3390/molecules28062499
Vancouver
Kljun J, Rebernik M, Balsa LM, Kladnik J, Rapuš U, Trobec T, et al. Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds. Molecules. 2023. doi:10.3390/molecules28062499
BibTeX
@article{Kljun2023,
author = {Kljun, Jakob and Rebernik, Mihaela and Balsa, Lucía M and Kladnik, Jerneja and Rapuš, Uroš and Trobec, Tomaž and Sepčić, Kristina and Frangež, Robert and León, Ignacio E and Turel, Iztok},
title = {Exploring pta Alternatives in the Development of Ruthenium–Arene Anticancer Compounds},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28062499}
}
EUVIMED